Kymera Results Presentation Deck

● ● STAT3 Degradation in Blood at Dose Level 1 (DL1: 0.05 mpk) Consistent with Prediction from Preclinical Modeling Mean % Change from C1D1 Predose STAT3 (fmol/µg) -20 -40 -60 -80- Clinical PD in PBMC by MS Method: Targeted MS n = 4 subjects -100+ 0 24 48 72 96 120 144 168 192 216 240 264 Hours Post Infusion KT-333 0.05 mpk KT-333 0.05 mpk Subject ID KYMERA ©2022 KYMERA THERAPEUTICS, INC. DL1-1 DL1-2 DL1-3 DL1-4 Mean Max Degradation* Post-doses 1&2 (Range) -79.8 % (-75.6 % to -84.1 %) -67.8 % (-73.5 % to -62.0 %) -50.0 % (-47.4% to -52.6 %) -66.7 % (-47.7% to -85.8 %) Cohort Average *Max degradation as measured across timepoints sampled -66.0 % Observed STAT3 degradation of 50-80% in PBMCs at Dose Level 1 is consistent with the range predicted for tumor based on preclinical modeling of SUDHL1 xenograft PK-PD data Maximal degradation in DL1 patients is observed between 24-96 hours post infusion in Cycle 1 weeks 1 & 2, with recovery of STAT3 levels between doses, as seen in preclinical models PAGE 13

View entire presentation